Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg
OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX®
(sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in
healthy subjects.
- To estimate the relative bioavailability of single-dose intranasal administration of 20
mg OPTINOSE SUMATRIPTAN, 20 mg IMITREX® (sumatriptan) Nasal Spray, and 100 mg IMITREX®
(sumatriptan) Oral Tablet compared to a single-dose of 6 mg IMITREX® (sumatriptan)
Subcutaneous Injection, in healthy subjects.